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Background: Illicit drug use is an important public health problem. Identifying conditions that coexist with illicit
drug use is necessary for planning health services. This study described the prevalence and factors associated with
social and health problems among clients seeking treatment for illicit drug use.
Methods: We carried out cross-sectional analyses of baseline data of 2526 clients who sought treatment for illicit drug
use at Helsinki Deaconess Institute between 2001 and 2008. At the clients’ first visit, trained clinicians conducted face-
to-face interviews using a structured questionnaire. Logistic regression was used to compute adjusted odds ratios
(AORs) and 95% confidence intervals (CIs) for factors associated with social and health problems.
Results: The mean age of the clients was 25 years, 21% (n = 519) were homeless, 54% (n = 1363) were unemployed and
7% (n = 183) had experienced threats of violence. Half of the clients (50%, n = 1258) were self-referred and 31% (n = 788)
used opiates as their primary drugs of abuse. Hepatitis C (25%, n = 630) was more prevalent than other infectious
diseases and depressive symptoms (59%, n = 1490) were the most prevalent psychological problems. Clients who were
self-referred to treatment were most likely than others to report social problems (AOR = 1.86; 95% CI = 1.50–2.30) and
psychological problems (AOR = 1.51; 95% CI = 1.23–1.85). Using opiates as primary drugs of abuse was the strongest
factor associated with infectious diseases (AOR = 3.89; 95% CI = 1.32–11.46) and for reporting a combination of social and
health problems (AOR = 3.24; 95% CI = 1.58–6.65).
Conclusion: The existence of illicit drug use with other social and health problems could lead to increased utilisation
and cost of healthcare services. Coexisting social and health problems may interfere with clients’ treatment response.
Our findings support the call for integration of relevant social, medical and mental health support services within drug
treatment programmes.
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Illicit drug use has become a major concern in Europe, with
high estimates of past year use of cannabis (23 million),
cocaine (4 million), MDMA (‘ecstasy’, 2.6 million) and
amphetamines (2 million) among 15 – 64 years olds [1].
Among the same age group in Nordic countries, lifetime
prevalence of cannabis use is 36.5% in Denmark, 16.2% in
Norway, 14.3% in Finland, and 12.5% in Sweden [2]. In* Correspondence: Ifeoma.onyeka@uef.fi
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reproduction in any medium, provided the orresponse, many countries have initiated drug treatment
programmes to counter negative health and social con-
sequences of illicit drug use. In Finland, those seeking
treatment for drug use have access to both specialised and
generic services. Specialised services are provided
through outpatient clinics, short-term inpatient care,
rehabilitation units and support services. Treatment
services are also available through primary, social and
health care services [3].
Use of illicit drugs is associated with emotional and
behavioural changes which make drug-taking assume
precedence over other areas such as school, work, familyLtd. This is an Open Access article distributed under the terms of the Creative
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education survey, initiated prior to high school entry,
indicate that drug users have fewer years of schooling
[5]; this might impact negatively on their career pros-
pects and predispose them to social disadvantage due to
difficulties in finding and maintaining jobs [6]. Due to
poor financial situation, their living conditions deterior-
ate, stable housing becomes unaffordable and some may
end up living on the streets [7,8]. Family responsibilities
are also affected: for those who live with children, the
risk of neglect/child abuse increases due to drug-related
poor parenting skills [9].
Illicit drug use has also been implicated in the spread
of blood-borne infectious diseases such as HIV and
Hepatitis C due to sharing of non-sterile injecting equip-
ment by injecting drug users (IDU) [10-12]. However,
the risk of infectious diseases is not limited to IDUs.
Transmission among non-injecting drug users has been
reported to occur when a person infected with a blood-
borne virus shares straw/tubing to snort drugs with an un-
infected person, where they share other items which could
convey blood such as toothbrushes, and through a sexual
relationship with a sero-negative partner [13]. Through
these routes, the risk of becoming infected is low compared
to sharing infected needles/syringes. Irrespective of route of
drug administration, the risk of blood-borne viruses being
transmitted between drug users, and indeed between drug
users and non-drug users through social and sexual interac-
tions, should be considered an important public health
issue. Other infections and health problems reported
among drug users include abscesses, cellulitis, bacterial
endorcarditis, necrotizing fasciitis, osteomyelitis, candidosis,
thrombophlebitis, and ulcers [14].
The prevalence of psychological disorders is known to
be high among those who use illicit drugs [15]. Such
disorders may precede drug use [16] and they may also
occur as a result of it [17]. Co-occurring psychological
disorders have been found to lower clients’ readiness to
change their addictive behaviours [18], resulting in poor
treatment outcomes. Clients experiencing both drug
addiction and psychological disorders tend to use more
services, have higher relapse and re-admission rates
thereby increasing the cost of treatment [19].
Identifying conditions that coexist with drug use is
necessary for planning and provision of additional
services based on identified needs. The epidemiological
part of the “huumehoito tietokanta” (HUUTI, translated
as drug treatment database) consortium research project
is the first large-scale longitudinal study of illicit drug
users seeking treatment in Finland. The aim of this
paper is to describe the prevalence and factors associa-
ted with social and health problems that coexist with
drug use based upon information provided by clients at
their first visit to Helsinki Deaconess Institute (HDI).Methods
Study design
The original sample consisted of a non-random sample
of 4817 clients who sought treatment at HDI between
31 January 1997 and 31 August 2008. However, to
minimize the amount of missing data for some variables
of interest, this analysis was restricted to a subset of
clients who attended the HDI between 2001 and 2008.
There were no selection criteria: all consecutive clients
who sought treatment at HDI during the study period
were included in the study. This paper is based upon
information provided by each of the clients during their
first visit (i.e. their first face-to-face interview) at HDI,
which serves as the baseline for subsequent longitudinal
analyses.
Subjects
A total of 2526 clients (1702 males and 824 females)
sought treatment at the HDI between 2001 and 2008. The
HDI is a large drug treatment provider in Helsinki and
clients came from the Greater Helsinki area including
some surrounding semi-rural communities. Treatment-
seeking at HDI was based on client self-referral, referral
from doctors or other treatment centres, and other
sources. Following initial assessment during the first visit,
treatment plans were drawn up and clients were assigned
to various drug treatment modalities for subsequent visits.
Ethical approvals were obtained from the Research Ethics
Committee of the Hospital District of North-Savo and the
Ethics Committee of HDI. Permissions were obtained
from the Ministry of Social Affairs and Health of Finland
and from appropriate municipal authorities of all Greater
Helsinki area communities where clients resided.
Instrument
Items on the questionnaire were adapted from the
European Addiction Severity Index (EuropASI), the Treat-
ment Demand Indicator Protocol (TDI) and other ques-
tions, which were relevant for evaluation of treatment
needs and clinical monitoring of clients. The EuropASI is
the European version of Addiction Severity Index (ASI)
[20,21] which contains questions on drug use, employ-
ment/support, family/social history, psychiatric disorders,
medical and legal issues. Researches have demonstrated
the reliability and validity of the EuropASI [22,23]. The
TDI, developed by the Pompidou Group of the Council of
Europe [24-26], contains questions on treatment contact,
sociodemographic information and drug use. The reliabi-
lity of self-reported data using TDI was estimated to be
90% [24].
Data collection
At first visit, trained clinicians interviewed clients using a
structured questionnaire to obtain self-reported information
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social history and medical and psychiatric histories.
Clients provided information about their main reason for
seeking treatment, referral to treatment, previous contact
with any drug treatment centre, and whether they were
receiving concurrent treatment elsewhere. To assess their
social situations and demographics, clients responded to
questions about their level of education; marital status;
employment; and main source of income at the time of
interview. They also responded to questions about their
children under 18 years and other drug users living in the
same household. Homelessness was defined as the pres-
ence or absence of postal code/address. Questions were
asked about threats of violence from anybody (i.e. external
sources). Infectious disease status was based on self-
reports from clients based upon their perception of previ-
ous laboratory investigations. Clients were asked if they
had been screened for infectious diseases (HIV, Hepatitis
A, Hepatitis B and Hepatitis C) in the past and for the
results of the tests. Data on depressive symptoms were
based on self-reports. The clinicians (nurses and physi-
cians who specialised in psychiatry and addiction medi-
cine) asked further questions to assess other mental health
conditions including psychosis and suicidal thoughts and/
or attempts.
Data analysis
Variables were expressed as a proportion of the denomi-
nator (2526). Factors associated with social problems and
heath problems (infectious diseases and psychological
problems) were initially assessed in univariate logistic
regression models. Thereafter, multivariate logistic regres-
sion analyses (forced entry method) were utilised to assess
the independent effect of variables that were statistically
significant in the univariate analyses. Those coded as zero
were the reference categories. The four dependent vari-
ables (recorded as yes = 1, no = 0) were social problems
(homelessness or unemployment or threats of violence);
infectious diseases (HIV or Hepatitis A or Hepatitis B or
Hepatitis C); psychological problems (depressive symp-
toms or psychotic symptoms or suicidal thoughts or
suicide attempt); and a combination of social and health
problems (i.e. combinations of social problems, infectious
diseases and psychological problems). Independent vari-
ables considered included age (in years), gender (male = 1,
female = 0); marital status (married = 1, unmarried = 0);
education (≥ high school = 1, < high school = 0); children
under 18 years (yes = 1, no = 0); referral to treatment (self-
referral = 1, other referrals = 0); use of alcohol as primary
drugs (yes =1, no = 0); use of cannabis as primary drugs
(yes = 1, no = 0); use of prescription medicines as primary
drugs (yes = 1, no = 0); use of opiates as primary drugs
(yes = 1, no = 0); use of stimulants as primary drugs (yes
=1, no = 0); use of other drugs as primary drugs (yes = 1,no = 0). Other primary drugs refer to hallucinogens,
solvents/inhalants, gamma-hydroxybutyric acid and
anabolic steroids. Results were expressed as adjusted odds
ratios (AORs) with 95% confidence intervals (CIs). All
analyses were carried out using SPSS version 17 for
windows (SPSS Inc., Chicago IL).
Results
Seeking treatment
Substance use was the main complaint (89%, n = 2237).
Other main concerns for seeking treatment were related to
social (4%, n = 91), psychiatric (1%, n = 32), physical (0.1%,
n = 2), aftercare (0.1%, n = 2) and other unspecified issues
(3%, n = 73). Half of the respondents (50%, n = 1258;
Table 1) sought treatment on their own. Non-voluntary
referrals were by family and friends (19%, n = 489); the
police (1%, n = 14); employers (0.3%, n = 7); child healthcare
(4%, n = 92); and others including healthcare, school and
social services. Thirty-two percent (n = 811) had previous
contact with drug treatment. In addition to their current
treatment, about 25% (n = 622) were receiving treatment
elsewhere (Table 1).
Demographic and living condition variables
As shown in Table 1, the mean age of the clients was 25
years (standard deviation [SD] ±8.4). Seventy percent (n =
1766) were educated below high school level. Less than
ten percent were married and others were either unmar-
ried (68%, n = 1707), separated/divorced (6%, n = 161) or
widowed (0.04%, n = 1). About two-thirds (68%, n = 1713)
reported that they did not have children less than 18 years.
However, others had children less than 18 years living in
the same household (6%, n = 159), in foster care (4%, n =
110), elsewhere (12%, n = 296), or unspecified places (1%,
n = 34). Forty-four percent (n = 1110) did not have other
people who use drugs living with them. Among those who
did, other individuals reported to be living in the same
household used illicit drugs (14%, n = 345), alcohol (3%,
n = 62) or both illicit drugs and alcohol (2%, n = 50).
Drug use patterns
Details of drug use patterns among all the clients have
been described elsewhere [27] but a brief description is
provided here. Lifetime prevalence was highest for
cannabis (78%). Almost 40% were using five drugs at the
time of interview, signifying polydrug use. Opiates were
the most frequently reported primary drug of abuse
(30%). Forty-five percent administered their primary
drugs intravenously and 44% used their primary drugs
daily during the past month. Cannabis was the most
common secondary drug (34%). The secondary drugs
were mostly smoked (39%) and were mostly consumed
once per week or less frequently (33%) during the past
month.
Table 1 Background characteristics of clients at first visit
to HDI, 2001 – 2008
Variable N = 2526
Age






Marital status, n (%)
Married or cohabiting 197 (8)
Unmarried a 1869 (74)
Missing data 460 (18)
Education b, n (%)
≥ High school 589 (23)
< High school 1766 (70)
Missing data 171 (7)
Children under 18 years, n (%)
Yes c 599 (24)
No 1713 (68)
Missing data 214 (8)
Referral to treatment, n (%)
Self-referral 1258 (50)
Other referrals d 1184 (47)
Missing data 84 (3)
Primary drugs of abuse, n (%)
Use of alcohol as primary drugs 659 (26)
Use of cannabis as primary drugs 382 (15)
Use of prescription medicines as primary drugs 55 (2)
Use of opiates as primary drugs 788 (31)
Use of stimulants as primary drugs 599 (24)
Use of Other drugs as primary drugs e 43 (2)
Missing data -
HDI – Helsinki Deaconess Institute.
a including – unmarried, separated/divorced or widowed.
b < high school = elementary school, ≥ high school = high/vocational school,
university and others.
c Including those children living in the same household, in foster care,
elsewhere or unspecified.
d Referral by friends and family, the police, employers and other sources.
e Others – including hallucinogens, solvents/inhalants, gamma-hydroxybutyric
acid and anabolic steroids.
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About one-fifth of the clients (21%, n = 519) did not
have postal codes/addresses and were considered to be
homeless (Table 2). Fifty-four percent (n = 1363) were
not employed at the time of seeking treatment. For 18%
(n = 446), their salaries were their main sources of
income. Other clients reported that their main incomewas from pension (3%, n = 77), income support (32%,
n = 811), unemployment benefit (12%, n = 294) and other
unspecified sources (14%, n = 353). Threats of violence
were reported by 7% (n = 183). Sociodemographic and
drug use characteristics associated with social problems in
univariate and multivariate logistic models were shown in
Tables 3 and 4 respectively. Those who reported social
problems were significantly more likely than other clients
to be self-referred to treatment (AOR = 1.86; 95% confi-
dence interval (CI) = 1.50–2.30]; to be male (AOR = 1.48;
95% CI = 1.19–1.84); to be older (AOR = 1.04; 95% CI =
1.03–1.06); not using alcohol (AOR = 0.49; 95% CI = 0.29–
0.83) and cannabis (AOR = 0.47; 95% CI = 0.27–0.82) as
primary drugs of abuse.Health problems reported at first visit
Infectious diseases
HIV was the least reported infectious disease and the
prevalence of positive screening tests was 2% (n = 48;
Table 2). The prevalence of positive tests for other infec-
tious diseases included 3% (n = 70) for Hepatitis A, 3%
(n = 84) for Hepatitis B and 25% (n = 630) for Hepatitis
C. Based on the route of administration of the primary
drugs, reports of a positive screening test for HIV (71%),
Hepatitis A (79%), Hepatitis B (74%) and for Hepatitis C
(74%) were higher among intravenous drug users than
the others. As shown in Table 4, factors associated with
reporting positive screening test for infectious diseases
included using opiates as primary drugs of abuse (AOR =
3.89; 95% CI = 1.32–11.46); having children under 18 years
(AOR = 1.40; 95% CI = 1.06–1.84); being self-referred to
treatment (AOR = 1.31; 95% CI = 1.03–1.67); and being
older (AOR = 1.08; 95% CI = 1.06–1.10).Psychological problems
Overall, depressive symptoms were the most prevalent
psychological problems (59%, n = 1490; Table 2). Seven-
teen percent (n = 430) reported psychotic symptoms at the
time of interview. Thirty percent (n = 745) reported having
suicidal thoughts and almost one-fifth (19%, n = 478) of
the respondents have attempted suicide. As shown in
Table 4, clients who reported psychological problems were
significantly more likely than others to be self-referred to
treatment (AOR = 1.51; 95% CI = 1.23–1.85); to be older
(AOR = 1.06; 95% CI = 1.04–1.08); and not to be male
(AOR = 0.65; 95% CI = 0.52–0.80).
Further analyses were carried out on those clients who
reported a combination of social and health problems.
Multivariate analysis (Table 4) showed that factors asso-
ciated with reporting both social and health problems
included using opiates (AOR = 3.24; 95% CI = 1.58–6.65)
and using stimulants (AOR = 2.28; 95% CI = 1.10–4.72) as
primary drugs of abuse; being self-referred to treatment
Table 2 Social and health problems reported by the clients, 2001–2008 (N = 2526)
Variable Yes No Missing data Total
n (%) n (%) n (%) n (%)
1. Social problems
Homelessness 519 (21) 1971 (78) 36 (1) 2526 (100)
Unemployment a 1363 (54) 1030 (41) 133 (5) 2526 (100)
Threats of violence 183 (7) 1819 (72) 524 (21) 2526 (100)
2. Infectious disease screening tests
HIV positive 48 (2) 1383 (55) 1095 (43) 2526 (100)
Hepatitis A positive 70 (3) 1219 (48) 1237 (49) 2526 (100)
Hepatitis B positive 84 (3) 1241 (49) 1201 (48) 2526 (100)
Hepatitis C positive 630 (25) 763 (30) 1133 (45) 2526 (100)
3. Psychological problems
Depressive symptoms 1490 (59) 726 (29) 310 (12) 2526 (100)
Psychotic symptoms 430 (17) 1761 (70) 335 (13) 2526 (100)
Suicidal thoughts 745 (30) 1458 (58) 323 (12) 2526 (100)
Suicide attempts 478 (19) 1579 (63) 469 (18) 2526 (100)
aNo – includes employed persons, students, retirees, housewives/househusbands.
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Discussion
This study reports baseline data on social conditions and
health problems from the first large-scale longitudinal
study of treatment-seeking illicit drug users in Finland.
Findings from this study highlighted some level of
housing instability among treatment-seekers. This lendsTable 3 Univariate logistic regression analyses of factors asso
psychological problems and all three of these outcomes (N =






Age (in years) 1.07 (1.06–1.09)* 1.10 (1
Male gender 1.50 (1.27–1.77)* 1.26 (1
Married or cohabiting 1.46 (1.07–1.99)* 1.76 (1
≥ High school education 0.97 (0.80–1.18) 0.98 (
Having children under 18 years 1.95 (1.59–2.39)* 2.74 (2
Self-referral to treatment 2.82 (2.38–3.34)* 2.17 (1
Use of alcohol as primary drugsa 0.39 (0.32–0.46)* 0.48 (0
Use of cannabis as primary drugsa 0.38 (0.31–0.48)* 0.16 (0
Use of prescription medicines as primary drugsa 1.05 (0.60–1.81) 0.47 (0
Use of opiates as primary drugsa 3.03 (2.50–3.68)* 2.60 (2
Use of stimulants as primary drugsa 1.72 (1.41–2.10)* 1.62 (1
Use of other drugs as primary drugsa 0.99 (0.53– 1.83) 0.45 (
* P ≤ 0.05. a Other drugs – including hallucinogens, solvents/inhalants, gamma-hydr
1Homelessness or unemployment or threats of violence. 2HIV or hepatitis A or hepa
suicidal thoughts or suicide attempts.credence to results from research studies in other coun-
tries, which found cases of homelessness and street-
dwelling among those who use drugs [28-30]. Galea and
Vlahov [31] argue that homelessness is an important
social circumstance that influences the health and well-
being of drug users. For example, homeless drug users
engage in risky behaviours such as trading sex for drugs
and money. IDUs who are homeless may consume drugs














.09–1.11)* 1.06 (1.05–1.07)* 1.07 (1.06–1.08)*
.04–1.52)* 0.75 (0.62–0.90)* 1.23 (0.98–1.55)
.29–2.41)* 1.22 (0.89–1.68) 1.31 (0.90–1.91)
0.79–1.21) 1.58 (1.27–1.95)* 0.89 (0.69–1.14)
.25–3.33)* 1.57 (1.26–1.94)* 2.05 (1.64–2.58)*
.80–2.61)* 2.08 (1.75–2.48)* 2.19 (1.75–2.73)*
.38–0.60)* 0.54 (0.45– 0.65)* 0.51 (0.39–0.67)*
.10–0.24)* 0.51 (0.41–0.63)* 0.18 (0.10–0.30)*
.22–0.99)* 1.21 (0.67 – 2.18) 0.73 (0.33–1.62)
.17–3.13)* 1.72 (1.42–2.07)* 2.45 (1.97–3.03)*
.33–1.98)* 1.82 (1.47–2.24)* 1.40 (1.11–1.77)*
0.19–1.06) 1.03 (0.54–1.95) 0.37 (0.12–1.21)
oxybutyric acid and anabolic steroids. OR – odds ratio. CI – confidence interval.
titis B or hepatitis C. 3Depressive symptoms or psychological symptoms or
Table 4 Multivariate logistic regression analyses of factors associated with social conditions, infectious diseases,

















Age (in years) 1.04 (1.03–1.06)* 1.08 (1.06–1.10)* 1.06 (1.04–1.08)* 1.06 (1.04–1.07)*
Male gender 1.48 (1.19–1.84)* 1.03 (0.80–1.31) 0.65 (0.52–0.80)* -
Married or cohabiting 0.93 (0.65–1.33) 0.99 (0.70–1.41) - -
≥ High school education - - 1.04 (0.81–1.32) -
Having children under 18 years 1.14 (0.86–1.53) 1.40 (1.06–1.84)* 0.86 (0.65–1.12) 1.21 (0.93–1.57)
Self-referral to treatment 1.86 (1.50–2.30)* 1.31 (1.03–1.67)* 1.51 (1.23–1.85)* 1.36 (1.07–1.74)*
Use of alcohol as primary drugs 0.49 (0.29–0.83)* 1.48 (0.49–4.45) 0.66 (0.39–1.12) 1.40 (0.66–2.95)
Use of cannabis as primary drugs 0.47 (0.27–0.82)* 0.55 (0.17–1.82) 0.68 (0.39–1.19) 0.49 (0.20–1.21)
Use of prescription medicines as primary drugs - 0.62 (0.15–2.63) - -
Use of opiates as primary drugs 1.67 (0.99–2.83) 3.89 (1.32–11.46)* 1.11 (0.65–1.90) 3.24 (1.58–6.65)*
Use of stimulants as primary drugs 1.23 (0.72–2.08) 2.76 (0.92–8.20) 1.29 (0.75–2.23) 2.28 (1.10–4.72)*
Use of other drugs as primary drugs a - - - -
* P ≤ 0.05. a Others drugs – including hallucinogens, solvents/inhalants, gamma-hydroxybutyric acid and anabolic steroids. Only variables statistically significant in
univariate analyses were included in multivariate analyses. OR – odds ratio. CI – confidence interval. 1Homelessness or unemployment or threats of violence. 2HIV
or hepatitis A or hepatitis B or hepatitis C. 3Depressive symptoms or psychological symptoms or suicidal thoughts or suicide attempts.
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equipment [32]. In our study, few clients received
threats of violence; this differed from the results of a
large-scale study conducted in Canada [33], where a
large proportion of illicit drug users reported actual
experiences of violence. Therefore, our finding might
suggest limited hostility from both drug-using and non-
drug using people in Finland.
Unemployment was common. There was a disparity
between the number of people who were employed and
those who reported salary as their main sources of
income; it could be that some clients who were not
officially classified as being employed (e.g. students) also
earned salary through part-time work. However, collect-
ively, nearly half of the respondents were dependent on
government funding in terms of income support and un-
employment benefits. Given their low economic capabi-
lities, it is likely that many clients will continue to depend
on public funding for sustenance. Therefore, drug-using
clients could mount financial pressure on social welfare
services.
Some clients reported living within the same house-
hold with other legal and illicit drug users. Association
with other drug users helps to sustain drug-using habits
[34] and may hamper success in the treatment
programme. One hundred and fifty-nine clients (6%)
reported having children less than 18 years living in the
same household; this might lead to early exposure and
transfer of drug-using habits to children. Previous stu-
dies have demonstrated that children living in such social
environments are predisposed to drug use in theiradulthood [35,36]. Since the likelihood of reporting infec-
tious diseases was 1.40 times higher among those with
children less than 18 years, they might have sought treat-
ment out of fear of losing their children or might have
been referred by child care and social services.
Treatment-seeking was voluntary (self-referral) for half
of the respondents. One possible explanation is that
organisation and delivery of drug treatment services in
Finland take place at municipality level, so that services
are brought closer to drug users. Since self-referral was a
significant predictor of reporting social and health pro-
blems, these concerns may have necessitated treatment
seeking. Referral from the criminal justice system was
one percent, which was lower than 37% reported among
treatment samples in USA [37]. This might reflect differ-
ences in national drug policies, with strong emphasis on
criminal justice interventions related to drug use in
USA. These findings have implications for treatment
outcomes. Health and other concerns provide transient
motivation to clients and some may not complete
treatment [38]. A British study found high drop out rates
among clients coerced into treatment through the
criminal justice system [39]. However, a US report [40]
highlighted criminal justice referral as one of the strongest
predictors of outpatient treatment completion, probably
due to sanctions for non-completion.
A quarter of the respondents (25%) were receiving
concurrent treatment elsewhere. This may be related to
the fact that the HDI also serves as a treatment needs
assessment centre, which receives referrals from other
smaller clinics. However, treatment providers should aim
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treatment from multiple centres may interfere with
clients’ ability to commit to a specific treatment plan
and would result in wastage of public funds. In addition,
clients receiving treatment from multiple centres could
receive double dose of prescription medication, which
might increase the risk of excessive consumption and
overdose or sales in illegal street market.
Hepatitis C was the most prevalent infectious disease
and may be connected to high use of intravenous drugs in
this study population. This finding is consistent with the
report of Aceijas and Rhodes [41], which identified high
prevalence of hepatitis C infections among IDUs in most
of the 57 countries reviewed. The reported HIV seropreva-
lence in this study was lower than that reported elsewhere
in Europe [42], possibly due to low prevalence in the gen-
eral Finnish population which is currently 0.1% [43]. Using
opiates as primary drugs of abuse was the strongest factor
associated with reporting positive tests for infectious dis-
eases, probably due to sharing of contaminated injecting
equipment. This calls for heightened awareness of the
needle exchange programmes in Finland.
Depressive symptoms were the most common psycho-
logical problems. Our result is consistent with previous
research, which suggested that depressive symptoms are
common among drug users [44]. Suicidal thoughts and
suicide attempts reported by clients may be related to
depressive symptoms, which were highly prevalent in
this study population. Male clients were 0.65 times less
likely to report psychological symptoms, consistent with a
previous study [45], which also reported higher prevalence
among female drug users. Therefore, it is important to
identify clients who would benefit from a combination of
mental health and drug abuse treatment in order to
prevent premature deaths from suicide.
Findings from this study have implications for the
publicly funded healthcare system in Finland. The exist-
ence of drug use with other social and health problems
could lead to high healthcare expenditure. Low socio-
economic status, as evidenced by unemployment, low
education level, and homelessness, influence risk-taking
behaviours and contribute to negative health conse-
quences among those who use drugs [31]. Therefore,
there is a need to get drug users into early treatment in
order to reduce the financial costs of care. A study
conducted among drug users entering treatment in the
US found a decline in total medical cost in the post-
treatment period [46]. Co-occurring psychological and
medical problems should be addressed to prevent
relapse and excessive utilisation of health services [19].
Limitations of the study
Incomplete information for some variables, especially
the infectious diseases, suggests that the clinical staffmay not have recorded some of the clients’ responses
during the initial interview. For example, some clients
may have answered no to some of the questions but this
was not explicitly recorded. The presence of missing
data highlights some of the challenges encountered
when using clinical data for research purposes. Improve-
ments in the completeness of medical data will enhance
its utility for research purposes. A report from the UK
argues that improvements in the standard of medical
documentation are essential for planning services and
for efficient patient care [47].
Our study relied on self-reported data, the veracity of
which cannot be assured. However, a study by Kokkevi
and colleagues [24] found a high reliability of self-reported
information by drug users. Previous research in the UK
suggests that drug users are not unwilling to discuss
stigmatised behaviours such as sharing of injecting equip-
ment with researchers [48]. We have no reason to assume
that clients seeking treatment (largely voluntarily) were
not honest in their responses in relation to their social,
health and medical status, particularly when public trust
in governmental/administrative institutions in Finland is
reasonably high. However, it is possible that clients got
their test results for HIV and Hepatitis wrong and cross-
validation with laboratory investigations would have been
useful. That said, the high prevalence of hepatitis C
infection in this study was comparable to other European
studies among illicit drug users validated with saliva and
blood specimens [49-51]. Psychological data were not
measured using validated scales, but the clinicians work-
ing within the treatment setting had the knowledge and
skills required to carry out psychological assessments.
Clients seeking treatment may differ in several ways from
drug users who are not in contact with the treatment
system and this limits the generalisability of our findings
to non-treatment seekers.
Conclusion
This study highlighted the coexistence of illicit drug use
with other social and health problems. Drug use problems
do not exist in isolation. It is essential to address adverse
social situations and health problems that may interfere
with clients’ ability to stay focused and comply with ther-
apy. Our findings support the call for integration of rele-
vant social, medical and mental health support services
with drug treatment programmes. Diverse opinions exist
regarding the increase in the overall cost of treatment due
to additional expenses on support services. However,
provision of such services could be more cost-effective, at
least in the long run, in reducing morbidity, boosting
retention rates and facilitating the recovery process.
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